Evidence map›Paper›PMID 41817881›Full record

Trial reportEuropean journal of pediatrics2026

The use of the S-Caine patch is safe and feasible in children younger than three: a nonrandomised clinical trial.

Britt Anciaux, Katrien Lanckmans, Ronald Buyl, Tom De Potter, Gerlant van Berlaer

Abstract readClinical Trial
In one paragraph

Trial report in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Britt AnciauxDepartment of Paediatrics, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium. britt.kristien.anciaux@vub.be.ORCID http://orcid.org/0009-0003-4269-6886
Katrien LanckmansDepartment of Clinical Biology, Universitair Ziekenhuis Brussel, Brussels, Belgium.ORCID http://orcid.org/0000-0001-7992-6364
Ronald BuylDepartment of Public Health, Biostatistics and Medical Informatics, Vrije Universiteit Brussel, Brussels, Belgium.ORCID http://orcid.org/0000-0002-6598-9505
Tom De PotterDepartment of Cardiology, Centrum voor Hart-en Vaatziekten (CHVZ), Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.ORCID http://orcid.org/0000-0001-9717-3917
Gerlant van BerlaerPaediatric Intensive Care Unit, Universitair Ziekenhuis Brussel, Brussels, Belgium.ORCID http://orcid.org/0000-0003-3674-9083

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effective pain control in infants and toddlers is challenging, with limited data on topical anaesthetic safety. This study evaluates the safety and feasibility of a single S-Caine patch, a eutectic 70 mg lidocaine/70 mg tetracaine mixture with heat-assisted delivery, in children under 3 years. In this nonrandomised clinical trial (2019-2024) at a single tertiary paediatric centre, 67 of 106 eligible children under 3 years (median 0.55 years [IQR, 0.13-1.09]; range 3 days-3 years; 58% male) with arterial or central venous catheters received a single S-Caine patch applied for 30 min. Primary outcomes were safety, measured by plasma lidocaine concentrations (Cmax) versus a 0.100 mg/L safety threshold, adverse events monitoring, and feasibility assessed by Likert scales. Secondary outcomes included subgroup analyses by demographic and procedural factors. Median plasma lidocaine concentrations at - 15, 15, 30, 60, 120, and 240 min were < 0.010, < 0.010, 0.018, 0.020, 0.016, and 0.013 mg/L, respectively. Median Cmax was 0.025 [0.014-0.038] mg/L, remaining well below the predefined safety threshold across all subgroups (p < 0.001). Two patients exceeded the threshold (0.270 and 0.110 mg/L) without clinical effects. Minor adverse events occurred in 49 patients (73%): exclusively transient local erythema; resolving or decreasing within 30 min. Feasibility was excellent (≥ 4/5) in 87% at application and 82% at removal.

conclusionIn this clinical trial including 67 children, the S-Caine patch was safe and feasible for use in patients under three, with plasma lidocaine concentrations well below strict clinically relevant thresholds and adverse events only occurring locally, supporting its role as a non-invasive analgesic for procedural pain. Future studies are needed to confirm safety in larger paediatric populations. CLINICAL

trial registrationEU Clinical Trials Register, EudraCT Number 2019-002094-55, https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002094-55/BE . WHAT IS KNOWN: • Procedural pain management in young children is challenging, as current options are often invasive, distressing, or carry systemic side effects. Safe, effective, and non-invasive analgesic strategies are limited, particularly for infants and toddlers undergoing common procedures. WHAT IS NEW: • The S-Caine patch provides a safe, non-invasive analgesic option for children under three, with plasma lidocaine levels well below strict safety thresholds and only minor transient local reactions, improving procedural comfort and reducing reliance on systemic pain interventions.

Indexed as

Anesthetics, LocalLidocainePain ManagementTetracaineTransdermal PatchChild, PreschoolDrug CombinationsFeasibility StudiesFemaleHumansInfantInfant, NewbornMalePain MeasurementPediatric AnesthesiaAnesthetics, LocalDrug CombinationsLidocaineTetracaineAnaesthetics, LocalFeasibilityLidocainePain managementPharmacokineticsSafety

Identifiers

PMID41817881
PMCPMC12982313

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.